Patrys : 18 February 2015 - Patrys Granted European Patent for PAT-SM6

ASX & Media Release ASX & Media Release Patrys Granted European Patent for Clinical Candidate PAT-SM6

• PAT-SM6 patent granted in Europe secures protection through to November 2027

• Broadly, the patent covers the PAT-SM6 antibody for use in treating a variety of cancers

Melbourne, Australia; 18 February, 2015: Patrys Limited (ASX: PAB), a clinical stage biotechnology company is pleased to advise that it has been granted a third European patent for its anti-cancer clinical candidate PAT-SM6.

The European Patent Office has issued correspondence confirming the grant of a key patent in the PAT-SM6 family; patent number 2101813; entitled "Novel glycosylated peptide target in neoplastic cells".

The European patent is derived from one of a series of patent applications that have been submitted to cover the PAT-SM6 product and target. The claims in this patent cover PAT-SM6 for use in treating various blood and solid cancers including myeloma, melanoma, lung, breast, pancreatic, kidney, colon, cervical and brain.

To date, nine patents across the PAT-SM6 families have been granted in four jurisdictions including the United States, Australia, Europe and Japan. Patrys has additional applications pending across the

PAT-SM6 families in Canada, Japan and the United States.

For further information, please contact: -Ends-

Patrys Limited:Patrys IR and Media: Roger McPherson Kyahn Williamson Chief Executive Officer Buchan Consulting

P: [phone] P: [phone]
[e-mail]

About Patrys Limited:

Based in Melbourne, Australia, Patrys (ASX: PAB) is focused on the development of natural human antibodies as therapies for cancer and other major diseases. Patrys has a deep pipeline of anti-cancer natural human antibodies that enable both internal development and partnering opportunities. More information can be found at www.patrys.com

About PAT-SM6:

PAT-SM6 is a natural human IgM antibody which has been shown to have potent anti-cancer properties in a large number of laboratory and animal studies. More specifically, Patrys has screened PAT-SM6 against more than 200 tumours from individual patients with various cancers, and the product binds to over 90% of the tumours screened regardless of cancer type, patient age, gender or disease stage. Patrys has filed patent applications to cover the PAT-SM6 antibody molecule, disease target and the mechanism of action. Patrys' PAT-SM6 has shown convincing evidence of potential therapeutic benefit in the recently completed Phase I/IIa clinical trial in patients with relapsed and refractory multiple myeloma. PAT-SM6 has been granted orphan drug status in Europe and the USA for multiple myeloma. Patrys has also successfully completed a Phase I clinical trial to evaluate PAT-SM6 as a therapy for melanoma. Patrys is now preparing for the next planned clinical trial.